MLLT10 in benign and malignant hematopoiesis.

Abstract

Non-random chromosomal translocations involving the putative transcription factor Mixed Lineage Leukemia Translocated to 10 (MLLT10, also known as AF10) are commonly observed in both acute myeloid and lymphoid leukemias and are indicative of a poor prognosis. Despite the well-described actions of oncogenic MLLT10 fusion proteins, the role of wild-type MLLT10 in hematopoiesis is not well characterized. The protein structure and several interacting partners have been described and provide indications as to the potential functions of MLLT10. This review examines these aspects of MLLT10, contextualizing its function in benign and malignant hematopoiesis.

• Authors: Jamie L Deutsch, Jessica L Heath
• Journal: Experimental hematology (Exp Hematol) Vol. 87 Pg. 1-12 (07 2020) ISSN: 1873-2399 [Electronic] Netherlands
• PMID: 32569758 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: Copyright © 2020 ISEH -- Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.

Chemical References

• MLLT10 protein, human
• Neoplasm Proteins
• Transcription Factors

Topics

• Animals
• Hematopoiesis
• Humans
• Leukemia, Lymphocytic, Chronic, B-Cell (metabolism, pathology)
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive (metabolism, pathology)
• Neoplasm Proteins (metabolism)
• Transcription Factors (metabolism)